InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference
August 12 2021 - 12:00PM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a clinical-stage company developing
cannabinoid-based pharmaceutical drug candidates as well as
manufacturing technologies for pharmaceutical-grade rare
cannabinoids, today announced that Eric. A. Adams, President
and CEO, and Dr. Eric Hsu, Senior Vice President of Pre-Clinical
Research & Development, will present at H.C. Wainwright
Ophthalmology Virtual Conference on Tuesday, August 17, 2021.
Mr. Adams and Dr. Hsu will provide an overview
of InMed’s ocular program including INM-088, a topical eye drop
formulation under development for the treatment of glaucoma. The
active pharmaceutical ingredient (“API”) in INM-088 is cannabinol,
also known as CBN, a rare cannabinoid showing promise in its
potential to provide neuroprotection and to reduce intraocular
pressure of the eye.
The on-demand presentation will be available at 7:00 a.m. ET on
August 17, 2021 and can be accessed from the HC Wainwrights events
platform
at https://journey.ct.events/view/8bb508fa-05c0-42dd-87aa-e856330568ab.
An archived replay of the presentation will be available on the
Company’s website immediately following the conference for 90
days.
InMed’s management team will also be conducting meetings with
institutional investors throughout the conference. To schedule a
meeting, please contact your H.C. Wainwright representative or
register for the event at HCW Events.
Information on this event will also be posted on InMed’s event
page, which can be found
at: www.inmedpharma.com/about/events.
About InMed: InMed
Pharmaceuticals is a clinical-stage company developing a pipeline
of cannabinoid-based pharmaceutical drug candidates, initially
focused on the therapeutic benefits of cannabinol (“CBN”), and is
developing IntegraSyn™ to produce pharmaceutical-grade
cannabinoids. The Company is dedicated to delivering new
therapeutic alternatives to patients that may benefit from
cannabinoid-based pharmaceutical drugs. For more information,
visit www.inmedpharma.com.
Investor Contact: Colin ClancySenior Director,
Investor RelationsT: +1 604 416 0999E: cclancy@inmedpharma.com
Edison Group:Joe Green/Laine
YonkerT: +1.646.653.7030/+1.646.653.7035E:
jgreen@edisongroup.com / lyonker@edisongroup.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
information") within the meaning of applicable securities laws.
Forward-looking information is based on management's current
expectations and beliefs and is subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements.
Forward-looking information in this news release includes
statements about: presenting at H.C. Wainwright Ophthalmology
Virtual Conference; developing INM-088 for the treatment of
glaucoma; INM-088 showing the potential to provide neuroprotection
and to reduce intraocular pressure of the eye; developing
IntegraSyn™ to produce pharmaceutical-grade cannabinoids; and
developing a pipeline of cannabinoid-based pharmaceutical drug
candidates. All forward-looking information herein is qualified in
its entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Mar 2024 to Apr 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Apr 2023 to Apr 2024